|
MYO1D expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.16759992972038E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.40729999875688E-08 |
| Normal-vs-Stage2 |
1.208600E-01 |
| Normal-vs-Stage3 |
3.51319999980504E-07 |
| Normal-vs-Stage4 |
2.52270000000721E-07 |
| Stage1-vs-Stage2 |
1.213800E-01 |
| Stage1-vs-Stage3 |
4.626200E-01 |
| Stage1-vs-Stage4 |
4.325900E-02 |
| Stage2-vs-Stage3 |
6.299700E-02 |
| Stage2-vs-Stage4 |
7.924700E-03 |
| Stage3-vs-Stage4 |
1.827610E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.186499787309E-10 |
| Normal-vs-AfricanAmerican |
4.162800E-03 |
| Normal-vs-Asian |
1.67233999999183E-05 |
| Caucasian-vs-AfricanAmerican |
2.912200E-01 |
| Caucasian-vs-Asian |
4.050800E-01 |
| AfricanAmerican-vs-Asian |
7.150400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.831090E-04 |
| Normal-vs-Female |
2.2316037906478E-11 |
| Male-vs-Female |
1.192770E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.79699999827798E-08 |
| Normal-vs-Age(41-60Yrs) |
1.4497999467622E-09 |
| Normal-vs-Age(61-80Yrs) |
1.275020E-03 |
| Normal-vs-Age(81-100Yrs) |
2.965600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.558000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.685200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.576600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.687400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.080800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.193200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.857800E-02 |
| Classical-VS-Follicular |
3.64108743156066E-12 |
| Classical-VS-Other |
4.778800E-01 |
| Classical-VS-Normal |
1.17683640610267E-14 |
| Tall-VS-Follicular |
1.33040001237816E-09 |
| Tall-VS-Other |
7.110200E-02 |
| Tall-VS-Normal |
5.84009995918677E-09 |
| Follicular-VS-Other |
1.070180E-01 |
| Follicular-VS-Normal |
3.513000E-01 |
| Other-VS-Normal |
2.438000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.359300E-04 |
| Normal-vs-N1 |
5.193100E-04 |
| N0-vs-N1 |
1.147200E-01 |
|
|
